Back to Peptides
Cetrorelix
Hormone Regulation & Endocrine SupportCetrorelix is a synthetic GnRH antagonist used to suppress LH and FSH secretion during controlled ovarian stimulation in IVF. It enables precise timing of ovulation and prevents premature hormonal surges that can compromise reproductive outcomes.
Reconstitute
1 mL BAC + 0.25mg vial
3 mcg/unit
Daily Range
0.25–0.5 mg Subcutaneous (SQ)
Once daily during ovarian stimulation (days 5–10 of cycle)
Standard Dose
0.25 mg
Cycle
4–8 weeks
then reassess
CetrorelixGnRH antagonistfertility treatmentLH suppressionIVF protocol
Dosing & Reconstitution Guide
Clinical studies often use 0.25–3 mg/day subcutaneously. Use is limited to regulated fertility and endocrine protocols.
Standard / Gradual Approach
0.25mg VialdailyPhaseDoseVolume
Days 5–6 onward0.25 mg dailyFull 0.25 mg vial SQ
Until trigger day0.25 mg dailyContinue daily until hCG trigger
Standard / Gradual Approach
3mg Vialsingle-dosePhaseDoseVolume
Stimulation day 73 mg onceFull 3 mg vial SQ (lasts ~4 days)
Protocol Summary
Subcutaneous (SQ): Once daily during ovarian stimulation (days 5–10 of cycle) · Dose range 0.25–0.5 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Inject 0.25 mg daily during ovarian stimulation (typically days 5–10 of cycle). Used in ART protocols under strict monitoring.
🧪 Quick Start
Vial Size
25 mg
BAC Water
1 mL
Concentration
25000 mcg/unit
Potential Benefits & Use Cases
Cetrorelix is a prescription fertility drug not approved for any use beyond regulated clinical settings.
Suppresses gonadotropin secretion in fertility-related research
Prevents premature ovulation in IVF clinical protocols
Studied for HPTA suppression in hormone regulation studies
Investigated for prostate health in androgen-dependent models
Provides precise control over reproductive hormone cycles
Clinical data Strong preclinical Limited data
Mechanism of Action
→Antagonizes GnRH receptors in the pituitary gland
→Suppresses secretion of LH and FSH from the anterior pituitary
→Prevents premature LH surge and ovulation during ovarian stimulation
→Supports controlled follicle development for IVF or ICSI procedures
Lifestyle & Optimization
timing
Used exclusively in IVF/fertility protocols under reproductive endocrinologist supervision.
diet
Adequate hydration supports ovarian function. Avoid alcohol and limit caffeine during stimulation cycles.
exercise
Reduce strenuous exercise during ovarian stimulation to minimize ovarian torsion risk.
sleep
Adequate rest during stimulation cycles.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Mild injection site reaction
• Headache
• Abdominal discomfort
Contraindications & Warnings
• May impair fertility if not properly dosed
• Should be used under medical supervision during ART cycles
Long-Term Safety Data
• Long-term hormone suppression risks unknown; short-term ART use well tolerated
🧮 Dose Calculator
Concentration
2.5
mcg/unit
Draw Volume
200
units (2.000 mL)
For a 500 mcg dose, draw 200 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High absorption with peak plasma concentration within 1–2 hours
Oral Administration
Ineffective orally due to enzymatic degradation
Half-Life
5–20 hours depending on dose and formulation
Degradation
Slow renal and hepatic peptide clearance
Tissue Specificity
Primarily acts on anterior pituitary GnRH receptors
⚗️
Peptide Details
Molecular Weight
1431.4
Formula
C70H92ClN17O14
Sequence
Ac-D-Nal-D-Phe-D-His-D-Trp-D-(2-Pal)-D-Tyr-D-Ser-OH
⚖️
Legal Status & Regulatory
RegionStatus
FDAApproved
EUApproved
AustraliaApproved
CanadaApproved
Storage Instructions
Lyophilized (Powder)
Store at 2–8°C (refrigerate). Protect from light. Stable until expiration date.
Reconstituted (Mixed)
Use immediately after reconstitution. Do not store.